Full Paper
RuL8: [{(p-cymene)RuCl2}2] (92 mg, 0.15 mmol) and [H2L8]Cl2
(137 mg, 0.31 mmol) afforded 170 mg (84%) of [(p-cymene)R-
C29H50Cl2N3O2RhS·2H2O: C 48.74, H 7.62, N 5.88; found: C 48.64, H
7.48, N 5.81.
1
u(L8)Cl]Cl as a yellow-orange powder. H NMR (CD2Cl2): d=7.78 (d,
RhL16: [{Cp*RhCl2}2] (92 mg, 0.15 mmol) and [H2L16]Cl2 (172 mg,
3J=8.4 Hz, 2H; C6H4), 7.51 (d, 3J=8.4 Hz, 2H; C6H4), 7.13 (brd, J
ꢀ10 Hz, 1H; NH), 5.90 (d, 3J=6.0 Hz, 1H; C6H4(cymene)), 5.76 (d,
3J=5.6 Hz, 1H; C6H4(cymene)), 5.69 (d, 3J=5.6 Hz, 1H; C6H4-
(cymene)), 5.43 (d, 3J=6.0 Hz, 1H; C6H4(cymene)), 4.83 (d, 2J=
0.31 mmol) afforded 220 mg (93%) of [Cp*Rh(L16)Cl]Cl as an orange
3
powder. 1H NMR (CD3OD): d=7.99 (d, J=8.4 Hz, 2H; C6H4), 7.55 (d,
3J=8.4 Hz, 2H; C6H4), 4.54 (s, 2H; CH2Ar), 3.29 (m, 2H; Me2NCH2),
3
3
3.03 (s, 6H; NMe2), 2.66 (t, J=5.6 Hz, 2H; NCH2CH2N), 2.49 (t, J=
5.6 Hz, 2H; NCH2CH2N), 1.88 (m, 2H; Me2NCH2CH2), 1.76 (s, 15H;
C5Me5), 1.26–1.46 (m, 26H; 13CH2), 0.90 ppm (t, 3J=6.8 Hz, 3H;
CH3); 13C{1H} NMR (CD3OD): d=145.7 (i-C(C6H4)), 132.3 (CH(C6H4)),
2
12.4 Hz, 1H; CHHAr), 4.78 (d, J=12.4 Hz, 1H; CHHAr), 3.40 (m, 2H;
Me2NCH2), 3.11 (s, 3H; NMe2), 3.10 (s, 3H; NMe2), 2.94 (brm, 1H;
NCHHCH2N), 2.93 (sept, 3J=6.8 Hz, 1H; Me2CH(cymene)), 2.65
(brm, 2H; NCH2CH2N), 2.20 (brm, 1H; NCHHCH2N), 2.11 (s, 3H; Me-
(cymene)), 2.02 (brt, Jꢀ10 Hz, 1H; NH), 1.78 (brm, 2H;
Me2NCH2CH2), 1.18–1.40 (m, 10H; 5CH2), 1.24 (d, 3J=6.8 Hz, 3H;
Me2CH(cymene)), 1.23 (d, 3J=6.8 Hz, 3H; Me2CH(cymene)),
2
129.4 (i-C(C6H4)), 128.2 (CH(C6H4)), 94.3 (d, J(Rh,C)=8.5 Hz, C5Me5),
66.8 (Me2NCH2), 64.4 (CH2NMe2), 49.7 (NMe2), 49.1 (NCH2CH2N), 45.6
(NCH2CH2N), 31.7 (CH2), 29.4 (5CH2), 29.3 (CH2), 29.2 (CH2), 29.1
(CH2), 29.0 (CH2), 28.8 (CH2), 26.0 (CH2), 22.3 (2CH2), 13.0 (CH3),
8.2 ppm (C5Me5); ESI-MS (MeOH): m/z (%): 754.37 (95) [M+], 718.39
(5) [M+ÀHCl]; elemental analysis calcd (%) for C37H66Cl2N3O2RhS: C
56.19, H 8.41, N 5.31; found: C 56.39, H 8.45, N 5.19.
3
0.89 ppm (t, J=6.8 Hz, 3H; CH3); 13C{1H} NMR (CD2Cl2): d=145.9 (i-
C(C6H4)), 132.5 (CH(C6H4)), 128.3 (i-C(C6H4)), 127.6 (CH(C6H4)), 101.4
(i-C(cymene)), 97.0 (i-C(cymene)), 82.3 (CH(cymene)), 82.2 (CH-
(cymene)), 80.8 (CH(cymene)), 80.4 (CH(cymene)), 67.1 (Me2NCH2),
64.4 (CH2NMe2), 49.8 (NMe2), 49.7 (NMe2), 48.9 (NCH2CH2N), 47.0
(NCH2CH2N), 31.7 (CH2), 30.4 (Me2CH(cymene)), 29.2 (CH2), 29.1
(CH2), 26.3 (CH2), 23.0 (Me2CH(cymene)), 22.9 (CH2), 22.6 (CH2), 21.6
(Me2CH(cymene)), 18.6 (Me(cymene)), 13.9 ppm (CH3); ESI-MS
(MeOH): m/z (%): 640.23 (55) [M+], 604.25 (45) [M+ÀHCl]; elemen-
tal analysis calcd (%) for C29H49Cl2N3O2RuS: C 51.54, H 7.31; found:
C 51.67, H 7.58.
Transfer hydrogenation tests
The reactions were carried out in Schlenk tubes under an inert at-
mosphere in degassed solvents. Typically the solution of HCO2Na
in water or water/methanol of desired concentration was prepared
directly in the reaction tube. The temperature was set and a fresh
5 mm solution of the precatalyst in degassed water was added to
reach a total volume of 4 mL. Finally the liquid substrate was di-
rectly added by syringe to the reaction mixture under vigorous stir-
ring. An aliquot of the reaction mixture (0.05 mL) was taken by sy-
ringe and diluted with methanol (0.4 mL) or extracted with ethyl
acetate (0.8 mL) before being analyzed by GC. The aliquots in
methanol were usually passed through a plug of silica before injec-
tion to remove traces of metal and salts. Each test was repeated at
least twice to check for reproducibility.
RuL16
:
[{(p-cymene)RuCl2}2] (92 mg, 0.15 mmol) and [H2L16]Cl2
(172 mg, 0.31 mmol) afforded 210 mg (89%) of [(p-cymene)Ru-
(L16)Cl]Cl as a yellow powder. 1H NMR (CD2Cl2): d=7.78 (d, 3J=
8.4 Hz, 2H; C6H4), 7.51 (d, 3J=8.4 Hz, 2H; C6H4), 7.11 (brd, J
ꢀ10 Hz, 1H; NH), 5.89 (d, 3J=6.0 Hz, 1H; C6H4(cymene)), 5.76 (d,
3J=5.6 Hz, 1H; C6H4(cymene)), 5.68 (d, 3J=5.6 Hz, 1H; C6H4-
(cymene)), 5.42 (d, 3J=6.0 Hz, 1H; C6H4(cymene)), 4.82 (d, 2J=
2
12.4 Hz, 1H; CHHAr), 4.77 (d, J=12.4 Hz, 1H; CHHAr), 3.39 (m, 2H;
Me2NCH2), 3.11 (s, 3H; NMe2), 3.10 (s, 3H; NMe2), 2.94 (brm, 1H;
NCHHCH2N), 2.92 (sept, 3J=6.8 Hz, 1H; Me2CH(cymene)), 2.65
(brm, 2H; NCH2CH2N), 2.20 (brm, 1H; NCHHCH2N), 2.10 (s, 3H; Me-
(cymene)), 2.01 (brt, Jꢀ10 Hz, 1H; NH), 1.80 (brm, 2H;
DOSY measurements
DOSY experiments were performed on a Bruker Avance 600 spec-
trometer at 258C by using the DOSY-ONESHOT[41] pulse sequence.
The following experimental parameters of the pulse sequence
were used: diffusion time 0.4 s, gradient pulse duration 2.5 ms, un-
balancing factor alpha 2.0, relaxation delay 5.0 s. Signal attenuation
was achieved by increasing the gradient strength from 5 to 80%
as defined by the pulse sequence in 16 steps with 16 scans each
and maximum gradient strength of 0.27 TmÀ1. The rows of the
pseudo-2D diffusion dataset were phased and baseline-corrected.
The pseudo-2D DOSY spectra were constructed by using standard
fitting procedure of the Bruker Topspin 2.1 software. The true diffu-
sion coefficients were determined by using the T1/T2 analysis
module of the Bruker Topspin 2.1 software. Viscosities of the solu-
tion were obtained by comparing the measured diffusion coeffi-
cients of the residual proton-containing solvents with the known
values (1.902ꢁ10À9 m2 sÀ1 for HDO in D2O[42] and 2.41ꢁ10À9 m2 sÀ1
for MeOH in CD3OD[43]). The hydrodynamic radii and volumes were
calculated from viscosity-corrected diffusion coefficients via the
Stokes–Einstein relation.
3
Me2NCH2CH2), 1.18–1.40 (m, 26H; 13CH2), 1.24 (d, J=6.8 Hz, 3H;
Me2CH(cymene)), 1.23 (d, 3J=6.8 Hz, 3H; Me2CH(cymene)),
3
0.88 ppm (t, J=6.8 Hz, 3H; CH3); 13C{1H} NMR (CD2Cl2): d=145.6 (i-
C(C6H4)), 132.6 (CH(C6H4)), 128.6 (i-C(C6H4)), 127.6 (CH(C6H4)), 101.9
(i-C(cymene)), 96.5 (i-C(cymene)), 82.5 (CH(cymene)), 81.9 (CH-
(cymene)), 81.1 (CH(cymene)), 80.5 (CH(cymene)), 67.2 (Me2NCH2),
64.3 (CH2NMe2), 49.5 (NMe2), 49.3 (NMe2), 49.0 (NCH2CH2N), 47.0
(NCH2CH2N), 31.9 (CH2), 30.4 (Me2CH(cymene)), 29.7 (5CH2), 29.5
(2CH2), 29.4 (2CH2), 26.4 (CH2), 23.2 (Me2CH(cymene)), 23.0 (CH2),
22.7 (2CH2), 21.9 (Me2CH(cymene)), 18.7 (Me(cymene)), 14.1 ppm
(CH3); ESI-MS (MeOH): m/z (%): 752.35 (55) [M+], 716.38 (45) [M+
ÀHCl]; elemental analysis calcd (%) for C37H65Cl2N3O2RuS: C 56.40,
H 8.31; found: C 56.44, H 8.35.
RhL8: [{Cp*RhCl2}2] (92 mg, 0.15 mmol) and [H2L8]Cl2 (137 mg,
0.31 mmol) afforded 180 mg (88%) of [Cp*Rh(L8)Cl]Cl as an orange
3
powder. 1H NMR (CD3OD): d=8.00 (d, J=8.4 Hz, 2H; C6H4), 7.55 (d,
3J=8.4 Hz, 2H; C6H4), 4.54 (s, 2H; CH2Ar), 3.30 (m, 2H; Me2NCH2),
3
3
3.03 (s, 6H; NMe2), 2.65 (t, J=5.2 Hz, 2H; NCH2CH2N), 2.49 (t, J=
5.2 Hz, 2H; NCH2CH2N), 1.88 (m, 2H; Me2NCH2CH2), 1.75 (s, 15H;
C5Me5), 1.28–1.45 (m, 10H; 5CH2), 0.92 ppm (t, 3J=6.8 Hz, 3H;
CH3); 13C{1H} NMR (CD3OD): d=145.7 (i-C(C6H4)), 132.4 (CH(C6H4)),
Determination of CMC
Surface tensions g at the air/solution interface were measured by
the Wilhelmy plate method (KSV Sigma tensiometer, Finland) at
25Æ0.58C. Solutions of RuL16 and RhL16 were prepared in the con-
centration ranges of 0.05–5 mm and 0.05–1.5 mm, respectively, in
deionized water (16 MW resistivity) and were equilibrated at room
temperature for 48 h. The platinum plate was cleaned and heated
2
129.4 (i-C(C6H4)), 128.2 (CH(C6H4)), 94.2 (d, J(Rh,C)=8.5 Hz, C5Me5),
66.8 (Me2NCH2), 64.4 (CH2NMe2), 49.7 (NMe2), 49.1 (NCH2CH2N), 45.6
(NCH2CH2N), 31.5 (CH2), 28.8 (2CH2), 26.0 (CH2), 22.3 (2CH2), 13.0
(CH3), 8.1 ppm (C5Me5); ESI-MS (MeOH): m/z (%): 642.25 (93) [M+],
606.26 (7) [M+ÀHCl]; elemental analysis calcd (%) for
Chem. Eur. J. 2014, 20, 846 – 854
853
ꢀ 2014 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim